MAPK8 and mantle cell lymphoma: Providing that BZ treatment of HMC-1.2 cells results in activation of JNK, which might exert a proliferation- and/or survival-promoting role, combined use of proteasome and JNK inhibitors might be used as effective treatment of MCL.